Research Updates - Subsequent-Line Treatment for EGFR-Mutant Lung Cancer

Explore the latest research developments in subsequent-line treatments for EGFR-mutant lung cancer through this 25-minute conference presentation from the 2025 Living with EGFR-Mutant Lung Cancer Patient Forum. Learn about cutting-edge therapeutic options and clinical trial findings for patients who have progressed beyond first-line treatment, as presented by Dr. Julia Rotow, clinical director for the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. Gain insights into emerging treatment strategies, resistance mechanisms, and promising new approaches that may improve outcomes for patients with EGFR-mutant lung cancer who require second-line and beyond therapies. Understand how recent research advances are shaping the evolving treatment landscape and what these developments mean for patient care and prognosis in this specialized area of thoracic oncology.